This completed Phase 3 clinical trial from Novo Nordisk investigated whether semaglutide — the active ingredient in Ozempic and Wegovy — could improve daily functioning and reduce body weight in people living with both obesity and heart failure. Participants were randomly assigned to receive either a weekly semaglutide injection or a placebo for approximately 59 weeks, with all participants also receiving lifestyle counseling on diet and physical activity. The dual focus on heart failure symptom burden and weight loss makes this trial particularly important, as obesity worsens heart failure outcomes and few pharmacological options have addressed both problems simultaneously. Results from this completed study have contributed to the growing evidence base supporting GLP-1 receptor agonists as potential game-changers in cardiovascular and metabolic medicine.
